



TAG Mail – 14 October 2021

NSW TAG ACTIVITIES

To all TAGMail readers:

NSW TAG is very sad to inform you that NSW Health have decided to move the core functions of NSW TAG from our clinician-led organisation to the CEC. NSW TAG will no longer receive core funding from NSW Health.

This means that **the last TAGMail will be delivered on 28th October.**

NSW TAG has supported and advanced quality use of medicines in NSW Hospitals through our expert network and secretariat for over 30 years. We are proud of the work produced by NSW TAG members and the secretariat during this time with many initiatives being adopted nationally.

NSW TAG is now entering a transition phase until 31/12/2021. There may be scope to continue some externally funded projects in 2022.

Thank you for your support over the 33 years NSW TAG has been in existence!



Upcoming meetings:

- NSW TAG Annual General Meeting: 12 -12.30pm 20th Oct 2021
- NSW TAG General Meeting: 10-12pm 20th Oct 2021
- NSW TAG Management Committee meeting: 8.30-10am 20th Oct 2021

Recent activities

Know your insulins – Poster with pictures: [Version 1.2 update](#)

incorporates different naming conventions for insulin types aligning to NSW based Thinksulin App

**COVID-19 medicines resources

Please always check the COVID-19 resources [webpage](#) for latest versions of resources (Note: new URL <https://www.nswtag.org.au/covid-19-medicines-resources/> previous URL still works & automatically redirects)

- **Sotrovimab** guideline updated (V1.2), patient information leaflet updated (brief version now also available), translations in progress
- **Baricitinib** guidelines updated (V1.2)

Recently [completed](#) email discussions

- Streamlining access to S8 medicines (e.g. when required for emergencies)

Jump to sections:

- [Other news](#)
- [Reports and publications - Australia](#)
- [Reports and publications - International](#)
- [Medication safety](#)
- [Papers of interest](#)
- [Consultations](#)
- [Webinars & Podcasts](#)
- [Upcoming events](#)

***The NSW TAG office landline is currently not regularly attended, please direct enquiries to nswtag@stvincents.com.au or directly to relevant staff member via email.*

COVID-19 RESOURCES & ARTICLES OF INTEREST

Please click this [link](#) for the cumulative listing of COVID-19 resources in past TAG Mails.

AUSTRALIAN

Australian Government Department of Health

- COVID-19 Australia: Epidemiology Report 51: Reporting period ending 26 September 2021 - [link](#)
- ATAGI update following weekly COVID-19 meeting – 6 October 2021 - [link](#)
- ATAGI clinical guidance on COVID-19 vaccine in Australia in 2021 (updated 12/10/21) - [link](#)

- Australian Health Protection Principal Committee (AHPPC) statement on recommendations for managing COVID-19 health risks - [link](#)
- ATAGI statement on the use of a 3rd primary dose of COVID-19 vaccine in individuals who are severely immunocompromised - [link](#)
- ATAGI Provider guide to COVID-19 vaccination of people with immunocompromise - [link](#)
- Updated [advice](#) on requirements for workers in health care settings who are exposed to COVID-19

NSW Health

- COVID-19 Weekly Surveillance in NSW - Epidemiological week 38, ending 25 September 2021 - [link](#)
- Management of Moderna elasomeran (Spikevax) COVID-19 vaccine from:
 - A standard temperature (-20°C) freezers to refrigerator (updated 8/10/21) - [link](#)
 - Refrigerator to administration (updated 8/10/21) - [link](#)
- Procedural sedation in the ED - [link](#)
- Aerosol generating respiratory procedures: Commencing resuscitation in ED - [link](#)
- Adult intensive care workforce report in COVID-19 pandemic - [link](#)
- Resumption and continuation of cardiac rehabilitation in NSW - Guiding principles - [link](#)

NSW Health Critical Intelligence Unit

- COVID-19 Monitor [14 Oct 2021](#): COVID-19 vaccines, cases, hospitalisations, deaths and variants
- Risk Monitoring Dashboard [13 Oct 2021](#)
- Living Evidence:
 - COVID-19 vaccines. Last updated 12 Oct 2021 - [link](#)
 - SARS-CoV-2 variants. Last updated 11 Oct 2021 - [link](#)
 - Rapid testing. Last updated 8 Oct 2021 - [link](#)
- Evidence Checks
 - COVID-19 vaccine booster shots - [link](#)
 - Acute mental health inpatient unit risk mitigation and models - [link](#)
 - COVID-19 vaccines in Australia (updated 8/10/21) - [link](#)

TGA

- COVID-19 vaccine weekly safety report - 07-10-2021 - [link](#)
- Provisional determination granted to Pfizer's COVID-19 vaccine ([COMIRNATY](#)) - proposed for use in children 5-11 years of age

SHPA

- Essential COVID-19 Member Briefing (with Prof Josh Davis, Elspeth Kay, A/Prof Steven McGoughlin, Dr Stephen Parnis) Wed 27 October 2021, 8 - 9pm AEDT - [register](#)

Other

- COVID-normal: preparing for a new world with Peter Doherty, Daniel Hunter & Faye McMillan, with Adrienne Torda, Wed, 27 October 2021, 6:00 PM – 7:00 PM AEDT – [register](#) free

INTERNATIONAL

Organisation for Economic Co-operation and Development (OECD)

- OECD COVID-19 Recovery Dashboard. How does your country fare in building back a stronger and more inclusive, green and resilient economy and society? - [link](#)

WHO

- A clinical case definition of post COVID-19 condition by a Delphi consensus, 6 October 2021 - [link](#)
- COVID-19 vaccine tracker and landscape 8 Oct 2021 - [link](#)
- Antigen-detection in the diagnosis of SARS-CoV-2 infection - [link](#)
- WHO COVID-19 Excess Mortality Estimation Methodology - [link](#)
- WHO SPRP 2021 Mid-term Report - WHO Strategic Action Against COVID 19 - [link](#)
- Science in 5: Episode [#57](#) – Malaria vaccine
- Job aid for COVID-19 vaccine administration: Comirnaty® BNT162b2 vaccine, Oct 2021 - [link](#)
- Bulletin of the World Health Organization:
 - Violence against children during the COVID-19 pandemic - [link](#)
 - Alignment of national COVID-19 vaccine recommendations for pregnant and lactating women - [link](#)
 - Pooled testing for SARS-CoV-2, options for efficiency at scale - [link](#)

- Operational framework for international travel-related public health measures in the context of COVID-19 - [link](#)

Europe

EMA

- COVID-19 vaccine safety updated for: [Spikevax](#) (Moderna), [Vaxzevria](#) (AstraZenica), [Janssen, Comirnaty](#) (BioNTech/Pfizer)
- New product information wording for Vaxzevria (from PRAC signal recommendations) Part 1- [link](#)
- EMA receives application for marketing authorisation for [Ronapreve](#) (casirivimab / imdevimab) for treatment and prevention of COVID-19

UK

- Department of Health and Social Care
- Coronavirus: lessons learned to date [report](#)
- Infectious Diseases Data Observatory (IDDO)
- Medical Product Quality Report - COVID-19 Issues. [Issue 12](#): October 2021 (Data from June & July)
- Specialist Pharmacy Services NHS UK
- Dosing information for COVID-19 booster vaccination - [link](#)
- Breastfeeding with COVID-19 infection - [link](#)
- Using Tocilizumab or Sarilumab for hospitalised patients with COVID-19 who are [breastfeeding](#)
- Using Tocilizumab or Sarilumab for hospitalised patients with COVID-19 who are [pregnant](#)
- UK Health Security Agency
- Pre COVID-19 vaccination booking checklist for parents of children aged 12 to 15 years - [link](#)

USA

- American Society of Health-System Pharmacists (ASHP)
- ASHP discussion forum ([Sign up](#) for free) recent topics of discussion: Baricitinib W/ Remdesivir; - Prioritizing patients to receive REGEN-COV; Anakinra, COVID-19, and MIS-A
- Education [activity](#): Ordering & Administering COVID-19 Therapeutics: Casirivimab & Imdevimab
- Education [activity](#): COVID-19 Vaccines in Children and Adolescents
- Centers for Disease Control and Prevention (CDC)
- Who Is Eligible for a COVID-19 Vaccine Booster Shot? - [link](#)
- Evidence to Recommendation Framework: Pfizer-BioNTech COVID-19 Booster Dose - [link](#)

JOURNAL ARTICLES

Annals of Internal Medicine

- COVID-19: Clinical and Public Health Implications of SARS-CoV-2 Immunology - [link](#)

Annals of the Rheumatic Diseases

- 2021 update of the EULAR points to consider on the use of immunomodulatory therapies in COVID-19 - [link](#)

bioRxiv preprints

- Comprehensive antibody profiling of mRNA vaccination in children - [link](#)

BMJ

- news: Covid-19: Sweden, Norway, and Finland suspend use of Moderna vaccine in young people "as a precaution" - [link](#)
- [Letter](#): COVID-19 vaccination and immunomodulatory or immunosuppressive drugs: indications and contraindications

Cannabis and Cannabinoid Research (Ahead of Print)

- Cannabidiol for COVID-19 Patients with Mild to Moderate Symptoms (CANDIDATE Study): A Randomized, Double-Blind, Placebo-Controlled Clinical Trial - [link](#)

Cellular and Molecular Immunology

- Significantly reduced abilities to cross-neutralize SARS-CoV-2 variants by sera from convalescent COVID-19 patients infected by Delta or early strains - [link](#)

European Heart Journal

- Myocardial microthrombi after COVID-19 mRNA vaccination - [link](#)

Infection & Chemotherapy

- Ruxolitinib and the Mitigation of Severe COVID-19: A Systematic Review and Meta-analysis - [link](#)

Intensive Care Medicine

- Tocilizumab and remdesivir in hospitalized patients with severe COVID-19 pneumonia: a randomized clinical trial - [link](#)

JAMA

- Association of Serum Ferritin Levels and Methylprednisolone Treatment with Outcomes in Non-intubated Patients with Severe COVID-19 Pneumonia - [link](#)

- Efficacy and Safety of Therapeutic-Dose Heparin vs Standard Prophylactic or Intermediate-Dose Heparins for Thromboprophylaxis in High-risk Hospitalized Patients With COVID-19. The HEP-COVID Randomized Clinical Trial - [link](#), [commentary](#)

- Association of Receipt of the Ad26.COV2.S COVID-19 Vaccine with Presumptive Guillain-Barré Syndrome, February-July 2021 - [link](#)

- [Research Letter](#): D-Dimer Testing for the Exclusion of Pulmonary Embolism among Hospitalized Patients with COVID-19

- Association between Risk of COVID-19 Infection in Nonimmune Individuals and COVID-19 Immunity in Their Family Members - [link](#)

- Effect of Antithrombotic Therapy on Clinical Outcomes in Outpatients with Clinically Stable Symptomatic COVID-19 - The ACTIV-4B Randomized Clinical [Trial](#)

Journal of Clinical Virology

- Natural spring water gargle and direct RT-PCR for the diagnosis of COVID-19 (COVID-SPRING study) - [link](#)

Lancet

- Do JAK inhibitors affect immune response to COVID-19 vaccination? Data from the MAJIK-SFR Registry - [link](#)

- Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID-19 pandemic - [link](#), [comment](#)

- All-cause and cause-specific mortality in people with mental disorders and intellectual disabilities, before and during the COVID-19 pandemic: cohort study - [link](#)

medRxiv

- Protection Across Age Groups of BNT162b2 Vaccine Booster against Covid-19 - [link](#)

- Illness characteristics of COVID-19 in children infected with the SARS-CoV-2 Delta variant - [link](#)

- Comparison of MIS-C Related Myocarditis, Classic Viral Myocarditis, and COVID-19 Vaccine related Myocarditis in Children - [link](#)

Nature

- Anti-SARS-CoV-2 receptor binding domain antibody evolution after mRNA vaccination - [link](#)

Nature Communications

- Nationwide rollout reveals efficacy of epidemic control through digital contact tracing - [link](#)

NEJM

- Protection of BNT162b2 Vaccine Booster against Covid-19 in Israel - [link](#)

- [Audio Interview](#): Are Covid-19 Vaccine Boosters Necessary?

- Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care Settings - [link](#)

- Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19 - [link](#)

- Waning of BNT162b2 Vaccine Protection against SARS-CoV-2 Infection in Qatar - [link](#)

Neurology

- Cerebral Venous Sinus Thrombosis and Thrombotic Events after Vector-Based COVID-19 Vaccines: A Systematic Review and Meta-analysis - [link](#)

Scientific Reports

- Beneficial effects of a mouthwash containing an antiviral phthalocyanine derivative on the length of hospital stay for COVID-19: randomised trial - [link](#)

OTHER NEWS (bold = new)

AHHA

- The Guidelines for a Palliative Approach to Aged Care in the Community (COMPAC) have recently been incorporated into the palliAGED online resource - [link](#)

Australian Commission on Safety and Quality in Health Care (ACSQHC)

- **New standards to keep Australians safe when accessing local health care** - [link](#)

Australian Institute of Health Innovation (AIHI)

- **New federal funding targets overuse of antipsychotics and antibiotics in aged care** - [link](#)

Health Action International

- Short [film](#): 'Access to Insulin 100 Years On: Leaving No One Behind' (launch [recording](#))

NPS MedicineWise

- Australian Prescriber Volume 44 Issue 5 [October 2021](#) includes:
 - Management of hypertension in pregnancy - [link](#)
 - Optimising oral health in frail older people - [link](#)
 - Fluoroquinolone antibiotics and adverse events - [link](#)
 - [Editorial](#): Improving the quality use of highly specialised drugs
 - Letters: Higher dose [statins](#) after stroke; Beyond [romosozumab](#)
- RADAR: Amended and new PBS listings for adrenaline autoinjectors - [link](#)

SHPA

- **2022 Branch Committee Elections: [Nominations](#) extended to 11.59pm Sunday 17 Oct 2021**
- Don't Rush to Crush 4th Edition Update: [Baricitinib](#) update Oct 2021 includes COVID-19 indication

WHO

- WHO recommends groundbreaking malaria vaccine for children at risk - [link](#)

REPORTS AND PUBLICATIONS – AUSTRALIA

Australian Institute for Health and Welfare (AIHW)

- Diabetes technology in Australia: scoping report - [link](#)

NSW Health

- Mental Health Clinical Documentation [PD2021_039](#)

TGA

- [Discontinuation of DILAUDID](#) hydromorphone hydrochloride 1mg/mL oral liquid - Updated information regarding alternative overseas products approved for supply
- [Database](#) of section 19A approvals to import and supply medicines to address medicine shortages
- AusPARs: [Pertuzumab/trastuzumab](#) ; [Elicarbazepine acetate](#)
- Australian prescription medicine decision summaries: [trientine](#) tetrahydrochloride (Cuprior) - for Wilson's disease in adults, adolescents and children ≥ 5 years intolerant to D-penicillamine therapy
- Registration of [new or extended uses](#) of registered medicine: 10 added
- Registration of [new chemical entities](#) in Australia: 4 added
- Registration of [new generic medicines and biosimilar](#) medicines: 14 added
- [Inclusions of new biologicals](#): burosumab (Crysvita), sacituzumab govitecan (Trodelvy)

REPORTS AND PUBLICATIONS – INTERNATIONAL

All Wales Medicines Strategy Group

- Consults on draft guidance on oral anticoagulation for non-valvular atrial fibrillation - [link](#)

electronic Medicines Compendium (eMC) (UK)

- New products
- Adakveo ([crizanlizumab](#)) - for prevention of recurrent vaso-occlusive crises (VOCs) in sickle cell disease patients aged ≥16 years as an add-on therapy to hydroxyurea/hydroxycarbamide (HU/HC) or monotherapy in patients for whom HU/HC is inappropriate or inadequate
- Koselugo ([selumetinib](#)) - monotherapy for symptomatic, inoperable plexiform neurofibromas in paediatric patients with neurofibromatosis type 1 (NF1) aged 3 years and above
- Rekambys ([rilpivirine](#))- in combination with cabotegravir injection for HIV-1 infection in virologically suppressed adults (HIV-1 RNA <50 copies/mL) on stable antiretroviral regimen without present/past evidence of viral resistance to, and no prior virological failure with, agents of NNRTI & INI class
- Vocabria ([cabotegravir](#)) for use in combination with rilpivirine injection for the treatment of virologically suppressed adults on a stable antiretroviral regimen without present or past evidence of viral resistance to, & no prior virological failure with agents of the NNRTI & INI class

Food and Drug Administration (FDA) USA

- New Drug approvals
- avacopan (Tavneos) to treat severe active anti-neutrophil cytoplasmic autoantibody-associated vasculitis (granulomatosis with polyangiitis and microscopic polyangiitis) in combination with standard therapy, including glucocorticoids - [link](#)

MIMS UK

- Summary: [Ryeqo](#) (relugolix/estradiol/norethisterone)

NHS Scotland

- Accepted:
- Bempedoic acid / ezetimibe ([Nustendi](#)®) for primary hypercholesterolaemia or mixed dyslipidaemia (restricted use)
- [Cabotegravir](#) (Vocabria®) accepted for treatment of HIV-1
- [Cabozantinib](#) (Cabometyx®) accepted for advanced renal cell carcinoma
- [Chloroprocaine](#) hydrochloride (Ampres®) for spinal anaesthesia (restricted use)
- [Empagliflozin](#) (Jardiance®) for symptomatic chronic heart failure with reduced ejection fraction
- [Midazolam](#) oral solution (Ozalin®) for sedation in children
- [Olaparib](#) (Lynparza®) for treatment of prostate cancer
- Not recommended:
- [Liraglutide](#) (Saxenda®) for weight management

National Institute for Health and Clinical Excellence (NICE) UK

- Cardiovascular disease: risk assessment and reduction, including lipid modification [\[CG181\]](#)
- Secukinumab for treating moderate to severe plaque psoriasis in children and young people [\[TA734\]](#)
- Final appraisal: Upadacitinib for previously treated moderate active rheumatoid arthritis [\[ID3878\]](#)

Obesity Health Alliance UK

- Turning the Tide: A 10-year Healthy Weight Strategy - [link](#)

Specialist Pharmacy Services NHS UK

- PGD templates:
- Administration of benzylpenicillin injection prior to transfer to secondary care in suspected bacterial meningitis or meningococcal septicaemia - [link](#)
- Administration of diazepam rectal tubes by registered Paramedics and Nurses for the management of seizures - [link](#)
- Administration of tranexamic acid by registered Paramedics and Nurses for treatment of severe haemorrhage - [link](#)
- Administration of buccal midazolam by registered Paramedics and Nurses for the management of seizures - [link](#)

- National PGDs:
- Administration of flumazenil by registered Paramedics or Nurses for the complete or partial reversal of the central sedative effects of midazolam used for conscious sedation - [link](#)
- Administration of diazepam emulsion for injection by registered Nurses for the management of seizures - [link](#)
- Administration of diazepam solution for injection by registered Paramedics and Nurses for the management of seizures - [link](#)

World Health Organisation (WHO)

- COP26 Special Report on Climate Change and Health (with 10 recommendations) - [link](#)
- Mental Health ATLAS 2020 published - [link](#)
- For the future: towards the healthiest and safest Region - Western Pacific for the next 5 years - [link](#)
- New stress management course for people living with adversity - [link](#)
- WHO report highlights global shortfall in investment in mental health - [link](#)

MEDICATION SAFETY

electronic Medicines Compendium (eMC) (UK)

- Revised SPCs
- Blincyto ([blinatumomab](#)) - licence extension as monotherapy in paediatric patients aged 1 year or older with high-risk first relapsed Philadelphia chromosome negative CD19 positive B-precursor acute lymphoblastic leukaemia as part of consolidation therapy
- Clexane ([enoxaparin](#)) - licence extension for use as extended treatment of deep vein thrombosis and pulmonary embolism & prevention of its recurrence in patients with active cancer
- Crysvida ([buromsumab](#)) now allows for self/carer-administration, once stabilised on treatment, after training on injection techniques, with first self-administered dose after drug initiation or dose change conducted under supervision of healthcare professional. Monitoring must continue as required
- [Daktacort](#) (miconazole/hydrocortisone) - severe hypersensitivity reactions, including anaphylaxis/angioedema reported with topical miconazole, close monitoring if patients on oral anticoagulants, adrenal suppression can occur even without occlusion and risk of topical steroid withdrawal syndrome
- Dupixent ([dupilumab](#)) - phase 3 open label extension study (AD-1225) of safety of repeat doses in 2677 adults exposed to 300 mg weekly found long-term safety profile up to 3 years was generally consistent with safety profile observed in controlled studies
- Esbriet ([pirfenidone](#)) - during pivotal clinical trials, cases of decreased appetite were readily manageable and generally not associated with significant sequelae. Uncommonly, cases of decreased appetite were associated with significant weight loss and required medical intervention
- [Genvoya](#) (emtricitabine, elvitegravir, cobicistat and tenofovir) - possible interactions with polyvalent cations and thienopyridines. The interaction with polyvalent cations may lead to lower plasma concentrations of elvitegravir due to local complexation in the gastrointestinal tract
- Inrebic ([fedratinib](#)) - warning added that if co-administered with agents that are renally excreted via organic cation transporter (OCT)2 and multidrug and toxin extrusion (MATE)1/2 K (e.g. metformin), caution should be exercised and dose modifications should be made as needed
- Kenalog (triamcinolone) = as well as 'Steroid Treatment Cards', the patient should carry a 'Steroid Emergency Card' when multiple doses are given in a relatively short period of time
- Kineret ([anakinra](#)) - eosinophilia and systemic symptoms (DRESS) has been added as a potential adverse effect of treatment, predominantly in patients with systemic juvenile idiopathic arthritis
- MabThera ([rituximab](#)) - limited data on excretion into breast milk suggest very low milk levels (relative infant dose <0.4%); a few follow-up cases describe normal growth/development up to 1.5 years. Available data do not suggest increased malignancy risk when used in autoimmune indications
- Trevicta and Xeplion ([paliperidone](#)) - Stevens-Johnson syndrome/toxic epidermal necrolysis added as a potential adverse effect of treatment (frequency unknown)

FDA Drug Safety Podcast

- FDA requires warnings about increased risk of serious heart-related events, cancer, blood clots, and death for JAK inhibitors that treat certain chronic inflammatory conditions – [link](#) to transcript
- Medications guides available for: Cannabidiol ([Epidiolex](#)); Dulaglutide ([Trulicity](#))

Medicines and Healthcare products Regulatory Agency (MHRA) UK

- Public Assessment Report of the reclassification of Calci-D chewable tablets from a Prescription Only Medicine (POM) to a Pharmacy (P) - [link](#)
- Drug Safety Update [October 2021](#)
- [Chloral hydrate, cloral betaine](#) (Welldorm): restriction of paediatric indication
- [Tofacitinib](#) (Xeljanz): new measures to minimise risk of major adverse cardiovascular events and malignancies
- #MedSafetyWeek 1-7 November 2021 (social media campaign): support the safety of [vaccines](#)

TGA

- Pentosan polysulfate sodium ([Elmiron](#)) & pigmentary maculopathy (esp after long-term use)– [update](#)

PAPERS OF INTEREST

American Journal of Health-System Pharmacy (AJHP)

- Outcomes of nontuberculous mycobacteria isolation among lung transplant recipients: A matched case-control with retrospective cohort study – [link](#)
- Management of patients with fibrosing interstitial lung diseases - [link](#)

Annals of Internal Medicine

- Rivaroxaban Is Associated With Higher Rates of Gastrointestinal Bleeding Than Other Direct Oral Anticoagulants - [link](#)
- Would You Recommend Aspirin to This Patient for Primary Prevention of Atherosclerotic Cardiovascular Disease? - [link](#)
- [Letter](#): Treating Type 2 Autoimmune Pancreatitis with Colchicine: A Case Series

Australian Health Review

- Chronic pain and cardiovascular disease prevention in primary care: a review of Australian primary health network needs assessments - [link](#)
- COVID-19 prompts rapid and safe transition of chemotherapy into homes - [link](#)

British Journal of Clinical Pharmacology

- Antihypertensive drug use and psoriasis: A systematic review, meta- and network meta-[analysis](#)
- Sodium-glucose co-transporter-2 inhibitors in the non-diabetic heart failure patient - [link](#)
- Association of proton pump inhibitor use with adverse health outcomes: A systematic umbrella review of meta-analyses of cohort studies and randomised controlled trials - [link](#)
- Clinical usefulness of prediction tools to identify adult hospitalized patients at risk of drug-related problems: a systematic review of clinical prediction models and risk assessment tools - [link](#)
- Effect of renal function on the risk of thrombocytopenia in patients receiving linezolid therapy: A systematic review and meta-analysis - [link](#)
- Switching between reference adalimumab and biosimilars in chronic immune-mediated inflammatory diseases: a systematic literature review - [link](#)
- Impact of regulatory interventions to restrict the combined use of renin–angiotensin system blockers: A Danish nationwide drug utilisation study - [link](#)
- Implementing prescribing safety indicators in prisons: a mixed methods study - [link](#)
- Physicians' and pharmacists' views and experiences regarding use of direct oral anticoagulants in clinical practice - [link](#)

British Medical Journal (BMJ)

- Advances in acute myeloid leukemia - [link](#)
- Effectiveness and safety of non-steroidal anti-inflammatory drugs and opioid treatment for knee and hip osteoarthritis: network meta-analysis - [link](#)

BMJ Open

- Audit of data redaction practices in NICE technology appraisals from 1999 to 2019 - [link](#)
- Shingles, Zostavax vaccination and risk of developing dementia: a nested case–control study—results from the UK Biobank cohort - [link](#)
- Characteristics of pharmacist's interventions triggered by prescribing errors related to computerised physician order entry in French hospitals: a cross-sectional observational study - [link](#)

- Quality standards for safe medication in nursing homes: development through a multistep approach including a Delphi consensus study - [link](#)
- Time-dependent propensity-matched general population study of the effects of statin use on cancer risk in an interstitial lung disease and pulmonary fibrosis cohort - [link](#)

British Journal of Psychiatry

- Comparative efficacy and acceptability of psychotherapies for panic disorder with or without agoraphobia: systematic review and network meta-analysis of randomised controlled trials - [link](#)

Canadian Journal of Health Technologies

- Bone Growth Stimulators for Treatment of Adults with Bone Disease or Injury - [link](#)

Circulation

- Effect of Long-Term Marine Omega-3 Fatty Acids Supplementation on the Risk of Atrial Fibrillation in Randomized Controlled Trials of Cardiovascular Outcomes: A Systematic Review and Meta-[Analysis](#)

Cochrane

- Pharmacotherapy for hypertension-induced left ventricular hypertrophy - [link](#)
- Ketamine and other glutamate receptor modulators for depression in adults with bipolar [disorder](#)
- Oral anticoagulation in people with cancer who have no therapeutic or prophylactic indication for anticoagulation - [link](#)
- Prophylactic antibiotics for preventing gram-positive infections associated with long-term central venous catheters in adults and children receiving treatment for cancer - [link](#)
- Recombinant growth hormone therapy for X-linked hypophosphatemia in children - [link](#)

Drug and Therapeutics Bulletin

- Accuracy of BP monitors used at home - [link](#)
- Outcomes in patients requiring intensive care for CAR T-cell toxicity - [link](#)

European Heart Journal

- Towards personalized antithrombotic management with drugs and devices across the cardiovascular spectrum - [link](#)

European Journal of Hospital Pharmacy

- Red for danger in systematic reviews? - [link](#)
- Comparison of metamamol versus no metamamol on time to resolution of shock in critically ill patients - [link](#)
- Real-world outcomes of abiraterone and enzalutamide in first-line treatment of metastatic castration-resistant prostate cancer: which patients benefit most? - [link](#)

Heart

- Optimal diet for cardiovascular and planetary health - [link](#)

Internal Medicine Journal

- Danger in discharge summaries: Abbreviations create confusion for both author and recipient - [link](#)

International Journal of Clinical Pharmacy

- Potentially inappropriate prescribing in a falls clinic using the STOPP and START criteria - [link](#)
- Evaluation of osimertinib for advanced non-small cell lung cancer with leptomeningeal metastases: a cost-effectiveness and budget impact analysis - [link](#) - [editorial](#)

JAMA

- Effect of Prophylactic Subcutaneous Scopolamine Butylbromide on Death Rattle in Patients at the End of Life. The SILENCE Randomized Clinical Trial - [link](#)

JAMA Network Open

- Comparison of New Pharmacologic Agents with Triptans for Treatment of Migraine. A Systematic Review and Meta-analysis - [link](#)
- Effect of medication reconciliation at hospital admission on 30-day returns to hospital: a randomized clinical trial - [link](#)

JAMA Psychiatry

- Long-term Arrhythmia Detection Using an Implantable Loop Recorder in Patients Receiving Psychotropic Medication - [link](#)

Journal of Patient Safety and Risk Management

- Implementation and evaluation of a good prescribing tip email to reduce junior doctors' prescribing errors - [link](#)

Journal of Pharmacy Practice and Research (JPPR)

- Infliximab switching from reference product to biosimilar: a review of evidence regarding the clinical efficacy, safety profile and immunogenicity - [link](#)

Lancet

- Series: A comprehensive approach to therapy of haematological malignancies in older patients - [link](#)
- Narrow-spectrum antibiotics for community-acquired pneumonia in Dutch adults (CAP-PACT): a cross-sectional, stepped-wedge, cluster-randomised, non-inferiority, antimicrobial stewardship intervention trial - [link](#)

Lancet Gastroenterology and Hepatology

- Current and emerging therapies for advanced biliary tract cancers - [link](#)

Lancet HIV

- Long-acting cabotegravir and rilpivirine dosed every 2 months in adults with HIV-1 infection (ATLAS-2M), 96-week results: a randomised, multicentre, open-label, phase 3b, non-inferiority study - [link](#)

Lancet Public Health

- Access to palliative care: the primacy of public health partnerships and community participation - [link](#)

Molecular Diversity Preservation International (MDPI) – Pharmacy Journal

- Outcomes of a National, Cross-Sector Antimicrobial Stewardship Training Initiative for Pharmacists in England - [link](#)

New England Journal of Medicine

- Autoimmune Hemolytic Anemias - [link](#)
- Spinal Anesthesia or General Anesthesia for Hip Surgery in Older Adults - [link](#)
- The Drug-Dosing Conundrum in Oncology — When Less Is More - [link](#)
- Immediate versus Postponed Intervention for Infected Necrotizing Pancreatitis - [link](#)

Pharmaceutical Journal

- National Patient Safety Incident Report (NaPSIR) finds decrease in number of reported medication-related incidents - [link](#)
- Return of ranitidine being considered by UK manufacturer - [link](#)

Prehospital Emergency Care

- A Standardized Formulary to Reduce Pediatric Medication Dosing Errors: A Mixed Methods [Study](#)

Public Library of Science (PLOS)

- The effects of an evidence- and theory-informed feedback intervention on opioid prescribing for non-cancer pain in primary care: A controlled interrupted time series analysis - [link](#)

CONSULTATIONS (new additions in bold)

NHMRC

- Comment sought on draft modules [Guideline impact](#), [Selecting studies and data extraction](#) and examples of relevant strategies that could be included impact module – email clinicalguidelines@nhmrc.gov.au until 16 December 2021

TGA

- Notice of interim decisions on proposed amendments to the Poisons Standard - ACMS #34 (oral contraceptive substances) - June 2021. Closes on 1 November 2021 - [link](#)

- Notice of interim decisions on proposed amendments to the Poisons Standard - ACMS #34 – re amygdalin & hydrocyanic acid, buprenorphine, ibuprofen - June 2021. Closes on 1 November 2021 - [link](#)
- **Notice of interim decisions on proposed amendments referred to the Advisory Committee on Medicines and Chemicals Scheduling in joint session (Joint ACMS-ACCS #28, June 2021), sodium nitrite, closes 11 Nov 2021 - [link](#)**

WEBINARS & PODCASTS

AHHA

- Getting evidence into policy and practice, 20 October 2021 10:30-11:30am - free - [register](#)
- [Webinar](#): Transformation for sustainability, 4/11/21

Australian Institute of Health Innovation (AIHI)

- [Webinar](#): Strengthening Care for Children – Can integrated care reduce hospital demand and improve outcomes for children? Wednesday, 20 October 2021, 2.00pm - 3.00pm (AEDT)

Brett Tindall Memorial Lecture 2021

- The Honourable Jillian Skinner, Fri, 22 October 2021, 11:00 AM – 12:30 PM AEDT – [register](#) free

FDA Division of Drug Information is presenting a [series](#) of CE webinars

- Fetal Pharmacology and Therapeutics Public Workshop, 21-22 October 2021 - [register](#)
- Overview of Risk Evaluation and Mitigation Strategies (REMS) for Health Care Providers - [link](#)

FIP

- 9th FIP Global Pharmacy Technicians' Symposium: [Day 1](#) (19/10/21) and [Day 2](#) (20/10/21)
- Episode 16 | FIP DG 8: Working with others 19 October, 13:00 - 14:30 CEST
- FIP "Setting goals for the decade ahead" | Episode 16 | FIP DG 8: Working with others. 19 October 2021 13:00-14:30 CEST - [register](#)
- Supporting self-care: disinfection in common conditions. 15 October 2021 11:00-12:30 CEST - [register](#)

MJA Podcasts

- [Episode 42](#): Potentially harmful compounds in e-liquids

Older Persons' Mental Health Service, Prince of Wales Hospital

- Keeping Connected: Social Health and Ageing, Wed 27th Oct, 10AM - 12PM, register free [here](#)

Pharmaceutical Journal – RPSGB

- [Podcast](#): Antidepressant withdrawal: why has it been ignored for so long?

Purple Pen Podcast

- [PPP123](#): Hyperbaric Medicine

TGA

- Nicotine vaping products, the [NZ](#) / [UK](#) smoking cessation experience; practical tips for Australian prescribers (webinars [14/10/21](#) and [20/10/21](#))

UPCOMING EVENTS

(New additions listed in TAGMail - click [here](#) for the running list of other events)

Nil new added

Back to [top](#) of page

The purpose of TAG Mail is to assist TAG members to identify and share relevant information for their professional practice. **Members are encouraged to routinely forward TAG Mail to others who they believe would benefit from this information such as colleagues in the same hospital department.** TAG Mail as a standing agenda item in clinical pharmacists' and other clinicians' meetings may help facilitate discussion of contemporary and emerging medicines and practice. You are receiving this email because you or a workplace colleague has requested TAG Mail. NSW TAG analyses uptake of TAG Mail (email openings and clicks on specific contents) in order to optimise the TAG Mail service for our members and colleagues. By requesting TAG Mail, you are also agreeing to have your data (email address, country of abode) captured. All information obtained is used in accordance with NSW Health Privacy Policy. Please contact NSW TAG at nswtag@stvincents.com.au if you have any questions regarding this. Click [here](#) if you are not already subscribed to automatically receive this newsletter in your inbox and would like to